What is Penumbra?
Penumbra is a neurovascular and vascular medical devices company serving providers, payers, patients, labs, hospitals, researchers, or life-sciences commercial teams.
- Category
- Neurovascular and vascular medical devices
- Headquarters
- Alameda, CA
- Founded
- See company profile and filings
- Employees
- Mid-market / scaled operating company
- Total funding
- Public company
- Status
- Public company; NYSE: PEN
What is Penumbra?
Penumbra is a neurovascular and vascular medical devices company headquartered in Alameda, CA.
Penumbra operates in neurovascular and vascular medical devices and has reached a scaled mid-market profile rather than an early startup footprint. Its official site and investor/company materials position the business around Stroke thrombectomy, Vascular thrombectomy, Embolization, with customers using the company for repeatable operating workflows rather than one-off projects.
For sellers, Penumbra is useful to profile because the buying center is large enough to include specialized finance, IT, operations, procurement, and line-of-business owners. The company status is Public company; NYSE: PEN, so the best live signals are current company announcements, investor materials where available, hiring patterns, product launches, and partner ecosystem activity.
What does Penumbra offer?
Penumbra's profile centers on Stroke thrombectomy, Vascular thrombectomy, Embolization, Access devices.
- Stroke thrombectomy· Neurovascular and vascular medical devices
- Vascular thrombectomy· Neurovascular and vascular medical devices
- Embolization· Neurovascular and vascular medical devices
- Access devices· Neurovascular and vascular medical devices
- Immersive healthcare· Neurovascular and vascular medical devices
- Peripheral vascular tools· Neurovascular and vascular medical devices
How does Penumbra make money?
Penumbra makes money through commercial activity tied to neurovascular and vascular medical devices.
Penumbra monetizes through the commercial model common to neurovascular and vascular medical devices: a mix of product sales, subscriptions, usage, services, channel programs, or transaction volume depending on the operating unit. Public list pricing is not always available, so enterprise buyers usually evaluate packaging, contract scope, geographic coverage, implementation services, and support commitments.
The practical growth levers are account expansion, new product attach, channel reach, retention, and operational efficiency. For outbound teams, that means relevant sales angles usually connect to productivity, integration, compliance, data quality, margin improvement, customer experience, or faster execution across distributed teams.
Who leads Penumbra?
Penumbra's named executives should be verified on the official leadership or investor-relations page before outreach.
- Penumbra executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Penumbra finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, and budget discipline.
- Penumbra technology or operations leadershipTechnology, product, operations, or security leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operational-improvement purchases.
How do you contact Penumbra's leadership?
Penumbra should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.penumbrainc.com- Penumbra investor relationsInvestor relations / corporate contactcontact via https://www.penumbrainc.com
- Penumbra media relationsMedia or communications contact routecontact via https://www.penumbrainc.com
How is Penumbra funded?
Penumbra's current status is Public company; NYSE: PEN.
Penumbra's current capital profile is best understood through its current status: Public company; NYSE: PEN. If the company is public, the relevant financing signals are annual reports, quarterly results, debt disclosures, buybacks, acquisitions, and capital allocation commentary rather than venture rounds.
If the company is private or recently acquired, the important seller signal is ownership context: sponsors or strategic owners often push standardization, operating metrics, procurement discipline, and integration work. In either case, budget timing should be inferred from current company announcements, earnings materials, product launches, hiring, and strategic initiatives rather than stale funding databases.
How did Penumbra get here?
Penumbra's history should be read through founding, scale-up, public/private ownership, and current product or market focus.
- FoundingPenumbra is foundedThe company begins building in neurovascular and vascular medical devices.
- Scale-upCommercial footprint expandsPenumbra broadens its product, customer, or geographic reach.
- Capital marketsPublic company; NYSE: PENOwnership and financing context shapes procurement, reporting, and operating priorities.
- 2025Mid-market operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, current status, and public source references.
Who are Penumbra's competitors?
Penumbra competes with larger platform incumbents and focused specialists in neurovascular and vascular medical devices.
- MedtronicGlobal medical-technology incumbent with broad device and care-management scale.
- Boston ScientificLarge medical-device company competing across interventional specialties.
- AbbottHealthcare company with diagnostics, diabetes care, devices, and nutrition scale.
- Johnson & Johnson MedTechLarge medtech and pharmaceutical incumbent with global commercial reach.
- StrykerOrthopedics, neurotechnology, and surgical equipment competitor with hospital relationships.
Penumbra — frequently asked questions
